Mosolov S N, Sharov A I, Kogan A D, Ryvkin P V
Zh Nevropatol Psikhiatr Im S S Korsakova. 1990;90(4):108-14.
Psychotropic activity of miansan (mianserin, lerivon) and pyrazidol was subjected to a comparative clinico-statistical study in depressions within the framework of phasically going endogenous psychoses. There were 2 clinically comparable groups each made up of 21 patients. Complete and appreciable efficacy was revealed in 16 patients (76.8%) receiving miansan and in 14 patients (67.2%) on pyrazidol. The general antidepressant effect of miansan correlated statistically significantly with sedative (anxiolytic and hypnotic) effect of the drug. As far as pyrazidol is concerned, the intensity of sedative and stimulating components of the antidepressant action did not essentially differ. No marked side effects were recorded even on drug administration in high doses, including persons with the signs of inferiority. The data obtained attest to the fact that miansan should be preferably used in anxious, anesthetic depressions and depressive paranoid conditions including those resistant to the preceding therapy with tricyclic antidepressants.
在阶段性进展的内源性精神病框架下，对米安色林（米氮平，乐瑞卡）和吡拉西坦的精神药理活性进行了一项关于抑郁症的比较临床统计学研究。有两个临床可比组，每组由21名患者组成。接受米安色林治疗的16名患者（76.8%）和接受吡拉西坦治疗的14名患者（67.2%）显示出完全且明显的疗效。米安色林的总体抗抑郁作用与该药物的镇静（抗焦虑和催眠）作用在统计学上有显著相关性。就吡拉西坦而言，抗抑郁作用的镇静和刺激成分强度没有本质区别。即使大剂量给药，包括有自卑迹象的人，也未记录到明显的副作用。所获得的数据证明，米安色林应优选用于焦虑、麻醉性抑郁症和抑郁性偏执状态，包括对先前三环类抗抑郁药治疗有抵抗性的情况。
